HRTX — Heron Therapeutics Share News
0.000.00%
Last trade - 00:00- $57.49m
- $158.52m
- $154.90m
Heron Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Heron Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Heron Therapeutics - Pursuant To Cooperation Agreement
Brief: Heron Therapeutics In Agreement With Rubric Capital, Velan Capital
Brief: Rubric Capital Reports 9.9% Stake In Heron Therapeutics As Of Jan 25
Brief: Heron Therapeutics' Preliminary Annual Net Product Sales 24% In 2022
U.S. STOCKS ON THE MOVE-Conagra Brands, Apple, Taylor Devices
Heron seeks FDA nod for expanded use of pain relief drug; shares jump
Brief: Heron Therapeutics Announces Filing Of Efficacy Supplement For Zynrelef And Provision In Newly Passed Congressional Bill
Brief: Heron Therapeutics Announces Financial Results For The Three, Nine Months Ended September 30, 2022
Heron Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Heron Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Heron Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Heron Therapeutics Says Selling Stockholders Are Offering 24.7 Million Shares On A Resale Basis
Brief: Heron Therapeutics Announces U.S. FDA Approval Of Aponvie™ (Htx-019) For The Prevention Of Postoperative Nausea And Vomiting (Ponv)
Brief: Deep Track Capital Reports 9.99% Passive Stake In Heron Therapeutics
Heron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Heron Therapeutics Announces Financial Results For The Three Months Ended June 30
U.S. RESEARCH ROUNDUP-Chevron, Occidental Petroleum, Talaris Therapeutics